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Vaccinations are administered to patients to induce
a protective immune response, resulting in
immunological memory. Preventing infection
through the use of vaccines is particularly important
in immunocompromised and immunosuppressed
individuals given their increased frequency and
severity of infections relative to healthy individuals.
Recent surveys show that the vaccination rate is still
alarmingly low in patients with rheumatic disease. In
this review we briefly discuss the different types of
vaccines and then critically examine evidence related
to vaccination efficacy in patients with autoimmune
disease and the effects of immunomodulatory
therapy, with an aim to provide guidance and
optimize the administration of vaccines in such
individuals.agement of these patients. This review will provide dataIntroduction
Immunizations are effective in inducing and/or enhan-
cing protective immunity, and may be particularly im-
portant in the immunocompromised. Autoimmunity
often imparts an increased risk for infection with addi-
tional medication-related risks, and common infections
have higher morbidity and mortality. Optimizing care
for patients with autoimmune disease requires treatment
of the underlying disease and minimizing infection-
related comorbidity, with vaccination as an important
component.* Correspondence: zmcmaha1@jhmi.edu
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(http://creativecommons.org/publicdomain/zeTreatments for rheumatic diseases have greatly ex-
panded in the last 15 years, encompassing biological
and nonbiological pathway inhibitors, all associated with
infections, and with consequent interest in mitigating this
risk. Patients taking immunomodulators have suboptimal
rates of immunizations, due in part to concerns over
vaccine-associated adverse events, possible activation of
the underlying autoimmune process, and questions of vac-
cine efficacy [1,2]. New guidelines and recommendations
provide conflicting information and/or inadequately ad-
dress specific rheumatologic concerns. Proportions of
rheumatologic patients vaccinated for influenza are 40%
or less, and in US Medicare recipients, only 33% of rheu-
matoid arthritis (RA) and psoriatic arthritis patients re-
ceived a pneumococcal vaccine over a 5 year period [1].
Our goals are to critically examine evidence regarding
immunization efficacy in autoimmune diseases and with
the array of immunomodulatory agents used in the man-
to inform decisions to optimize vaccine efficacy, avoid
adverse events, and reduce infectious risk.Methods
We conducted this review to evaluate immunization effi-
cacy in rheumatic conditions and with different immuno-
modulators, including both biological and non-biological
agents. An initial exhaustive literature search used PubMed
with terms listed in Table 1. Relevant abstracts from 2007
to 2013, American College of Rheumatology (ACR) and
European League Against Rheumatism (EULAR) meetings
were included as well as guidelines and recommendations
from immunological, infectious diseases, and rheuma-
tologic societies, and the Centers for Disease Control
(CDC), and descriptions of studies and results from
ClinicalTrials.gov. Additional articles were obtained from
reference lists and authors’ personal collections. An initialed Central Ltd. The licensee has exclusive rights to distribute this article, in any
n. After this time, the article is available under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
nal work is properly cited. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
Table 1 Search terms
Search terms
immunization, vaccines, vaccination, systemic lupus erythematosus,
vasculitis, rheumatoid arthritis, limited and diffuse scleroderma,
systemic sclerosis, myositis, juvenile rheumatoid arthritis, discoid lupus
erythematosus, autoimmune diseases, transplants, pediatric,
hydroxycorticosteroids, glucocorticoids, cyclosporine, sirolimus,
tacrolimus, mycophenolate mofetil, azathioprine, 6-mercaptopurine,
methotrexate, hydroxychloroquine, sulfasalazine, leflunomide, TNFR-Fc
fusion protein, etanercept, abatacept, rituximab, tocilizumab, infliximab,
adalimumab, CDP870, certolizumab, and golimumab, limited to articles
after 1980
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selected for clinical studies and reviews evaluating re-
sponses to vaccines in patients with autoimmune diseases
and transplants receiving immunomodulatory therapy.
After selection was complete, 147 papers were reviewed in
depth. Among studies there was significant heterogeneity;
in some studies immune responses were reported for pa-
tients receiving different medications, and in some par-
ticipants were taking multiple agents. We extracted data
from these articles by drug if possible for presentation,
and have presented summaries for each of the drugs and/
or classes using the most salient examples and references.
Given the paucity of published information for many im-
munomodulatory therapies currently being used, we have
also included abstract data from ACR and EULAR meet-
ings to provide clinicians with additional data to inform
clinical decision-making.
Immunizations: general overview
Vaccines vary in their components, including recombinant
or purified protein antigens, live attenuated or killed or-
ganisms, carbohydrate and polysaccharide antigens, and
conjugates (Table 2). Each mechanism activates different
immunological pathways with efficacy and safety implica-
tions and may invoke a neoantigen or booster response.
Live organism vaccines, typically viruses with attenuated
virulence but also live bacteria, generally induce high titer
and long-lasting immune responses (Table 3). Most are vi-
ruses (for example, zoster, varicella, yellow fever, measles/
mumps/rubella (MMR), intranasal influenza, oral polio,
and rotavirus) but some are live bacteria (for example, oral
typhoid, Bacillus Calmette-Guérin). Their recognition is of
paramount importance for immunosuppressed patients
because they may induce illness even from an attenuated
strain [3]; thus, live vaccines are not recommended for pa-
tients on many disease-modifying anti-rheumatic drugs
(DMARDs) and immunomodulators.
There is a paucity of data available, but the CDC has
provided recommendations for the immunosuppressed
with some vaccines and particular drugs; however, cate-
gorization of immunosuppression is quite broad and
includes congenital immunodeficiencies, HIV infection,
chemotherapy-induced marrow ablation, transplant-relatedimmunosuppression, and rheumatic disease patients re-
ceiving immunomodulators. The attenuated live varicella
zoster vaccine is recommended for adults aged over 60
years, regardless of prior chicken pox infection, immu-
nization, serology, or shingles history and may be used in
patients aged 50 to 59 years with potentially poor tolerance
to zoster infection or post-herpetic neuralgia. CDC gui-
dance has been published for zoster vaccine use in the
immunosuppressed [4]. The vaccine may be given to pa-
tients with decreased humoral immunity (that is, isolated
immunoglobulin (Ig) deficiency), patients receiving low to
moderate dose steroids (<20 mg/day prednisone), and pa-
tients on >20 mg prednisone for ≥2 weeks after 1 month
of discontinuation. The zoster vaccine can be used with
doses of methotrexate (MTX), azathioprine (AZA), and
6-mercaptopurine typically used in autoimmune disease
treatment.
Concerns remain regarding live vaccine safety with
other biological therapies and immunosuppressants. Al-
though recent reports using managed care and Medicare/
Medicaid databases suggest that patients receiving tumor
necrosis factor (TNF) inhibitors may be able to receive the
zoster vaccine without adverse effect [5,6], further pro-
spective studies are needed. In juvenile rheumatic disease
patients on MTX and corticosteroids the live varicella vac-
cine did not cause any overt infections [7]. While there is
a concern for potential conversion to a virulent form of
varicella in the immunocompromised, effective antiviral
drugs such as acyclovir and valacyclovir are available to
treat acute infections should they arise. In patients recei-
ving the zoster vaccine, these antivirals should be discon-
tinued before immunization and several weeks thereafter
to maximize response. MMR vaccines have also been ad-
ministered to children with pediatric rheumatic diseases
receiving immunodulators. In one study, there were no
cases of viral activation or illness with MMR in children
with juvenile idiopathic arthritis (JIA) taking MTX or
etanercept [8]. An important caveat for zoster and MMR
vaccine studies is that these largely represented recall or
booster responses of preexisting immunological memory,
which may have attenuated the risk of virulent conversion.
The yellow fever vaccine is also a live virus and required
for travel to many regions in the world, thus representing
a neoantigen for most. Although the live yellow fever
vaccine was given without sequelae to 17 Brazilian RA
patients receiving infliximab, this was as part of a re-
immunization effort rather than a neoantigen response;
these results cannot be extrapolated to immunocompro-
mised individuals receiving yellow fever vaccine for the
first time [9]. There are limited data concerning the risk to
immunosuppressed individuals of acquiring infection from
a family member or close contact who receives a live virus
vaccine [10]. In studies of live attenuated intranasal in-
fluenza vaccine administration in pediatric cancer [11],
Table 2 Types of vaccines and examples





Tetanus, diphtheria, acellular pertussis (TD/DT, TDAP,
DTAP)
Varicella (VZV, Varivax®, Varilrix®)
Meningococcal polysaccharide (MPSV-4) Hepatitis A, hepatitis B Shingles, zoster (for example, Zostavax®)
Typhoid polysaccharide (Vi injection) Seasonal influenza A/B injection Intranasal influenza (for example, Flu-mist®)
Pandemic influenza (H1N1) injection
Human papilloma virus Measles, mumps, rubella
Anthrax (acellular) Yellow fever
Inactivated polio (IPV, Salk, IM/SQ) Oral polio (OPV)
Oral cholera (killed cells) Typhoid (Ty21a oral)
Pneumococcal conjugate** (PCV-7, PCV-13, for
example, Prevnar®)
Vaccinia (smallpox)
Meningococcal conjugate** (MCV-4, <55 years old) Bacillus Calmette-Guérin
Haemophilus influenza type B protein




Vaccinations may vary in terms of their constituents from country to country (for example, Japanese encephalitis virus, rabies, anthrax) and over time as new
vaccines are developed. Providers are advised to consult product inserts of specific vaccines to confirm constituents before use. DTAP, diphtheria, tetanus, and
pertussis; HiB, Haemophilus influenza type B; IM/SQ, intramuscular/subcutaneous; IPV, inactivated polio virus; MCV-4, quadrivalent meningococcal conjugate;
MPSV-4, quadravalent meningococcal polysaccharide vaccine; OPV, oral polio virus; PCV, pneumococcal conjugate vaccine; PPSV, pneumococcal polysaccharide
vaccine; PRP, polyribosylribitol phosphate; TD/DT, Tetanus Diphtheria/Diphtheria Tetanus; TDAP, Tetanus diphtheria acellular pertussis; Vi, Vi capsular polysaccharide;
VZV, varicella zoster vaccine. **conjugated vaccines.
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is not recommended by the CDC in the immunocom-
promised or adults aged over 50 years [12]. Household
contacts of immunosuppressed patients without immunity
may also receive live virus vaccines, as transmission of
attenuated vaccine strain virus is rare, but caution
should still be exercised. Recently published recommen-
dations concerning viral transmission risk to patients
with immunodeficiencies from family contacts recei-
ving vaccines noted that these events were possible but
rare [10].
Recombinant protein antigen vaccines and killed virus
vaccines are also used but may have decreased immu-
nogenicity (relative to live vaccines) and require multiple
doses. Polysaccharide or carbohydrate antigen vaccines
were developed for some encapsulated organisms, inclu-
ding pneumococcus (23-valent pneumococcal polysaccha-
ride vaccine (PPSV-23), Pneumovax®), and meningococcus
(quadravalent meningococcal polysaccharide vaccine-4).
Polysaccharide immunization responses largely reflect
T-cell-independent mechanisms. Protein-conjugate vac-
cines, such as 7- and 13-valent pneumococcal conjugate
(PCV-7, PCV-13 or Prevnar®), meningococcal conjugate
(MCV-4), and conjugated Haemophilus influenza type B
(HiB) attach polysaccharide antigens to a carrier protein
to enhance response. The CDC Advisory Committee on
Immunization Practices now recommends PCV-13 to all
immunocompromised adults aged over 19 years, followed
≥8 weeks later by PPSV-23 to induce optimal memory,with subsequent PPSV-23 every 5 years [12,13]. In patients
who received prior PPSV-23, at least 1 year is recom-
mended before giving PCV-13.
Measuring vaccine responses
One difficulty in evaluating various vaccine studies is a
lack of standardized reporting. Although vaccines elicit
cellular and humoral immunity, efficacy is primarily
measured by antibody titers. Four general parameters
are used to measure vaccine response: 1) geometric mean
titers (GMTs), 2) seroprotection rate, 3) seroconversion
rate, and 4) seroconversion factor. A four-fold rise in
GMT is one measure of vaccine efficacy, though some
studies report two-fold increases. The seroprotection rate
represents the percentage of recipients with an antibody
titer at which the probability of protection is assumed to
be 50%, but protective levels are poorly standardized and
may vary among studies and between vaccines, and indeed
between individuals. Seroconversion rates describe the
percentage of recipients with a two- to four-fold or more
increase in post-vaccination titers. The seroconversion
factor is defined as the post-vaccination titer divided by
the pre-vaccination titer. Some studies have shown ad-
equate seroprotection but without expected increases in
antibody titers, attributed to cellular immunity. Other
studies have only reported increases in titers for patients
without baseline levels of protective titers (rather than all
patients receiving the vaccine), leading to difficulties in
comparing study results. For the majority of vaccines, the









Corticosteroids --/↓ -- ND ND Zoster OK with CCS <20 mg/day
Methotrexate ↓↓ ↓ -- -- Zoster OK with MTX <0.4 mg/kg/week
Anti-malarials -- -- ND ND Probably safe, possible ↓ response
Sulfasalazine --/↓ ND ND ND Probably safe, not formally studied
Leflunomide -- ND ND ND ND
Azathioprine -- --/↓ ND ND Zoster OK <3 mg/kg/day
Mycophenolate ↓↓ ↓↓ ↓ ↓ Avoid
Calcineurin Inhibitors --/↓ ND ↓ ND Avoid
Biologicals and targeted immunomodulators
TNF inhibitors --/↓ --/↓ -- ND Avoid
Abatacept (CTLA4-Ig) ↓ ↓ ND ↓ Avoid
Rituximab (anti-CD20) --/↓ ↓↓ ↓ ↓↓ Avoid
Tocilizumab (anti-IL6) -- -- ND ND Avoid
Ustekinumab (anti-IL-12/23) -- -- ND ND Avoid
IL-1 inhibitors (anakinra, Rilonacept, canakinumab) ND ND ND ND Avoid
Belimumab (anti-BLyS) ND ND ND ND Avoid
Tofacitinib (Jak1/3) --/↓ ↓ ND ND Avoid
↓ decreased, ↓↓ markedly decreased, -- no effect. BLyS, B lymphocyte stimulator; CCS, corticosteroids; DTH, delayed type hypersensitivity; MTX, methotrexate; ND, not
determined; TNF, tumor necrosis factor.
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and nasal and/or serum IgA, are poorly defined. Hence, in
a majority of cases, only serum antibody-mediated assess-
ments serve as correlates due to the complexity of assess-
ment of cell-mediated immune responses.
Antibody responses reported as endpoints in most
studies reflect a defined point in time (typically 4 weeks
after immunization), but do not necessarily reflect titer
maintenance. Although mounting an early response is
assumed to result in development of immunological
memory, few studies have evaluated titer durability over
time or the efficacy of boosting in immunocompromised
patients. Strategies to increase vaccine responses include
addition of adjuvant, booster vaccinations, increasing
antigen dose, and intradermal administration.
Results
Rheumatic diseases are managed with a variety of
immunomodulators, ranging from corticosteroids to




Immune responses of autoimmune disease patients
taking steroids have been well studied [14]. Even at low
doses overall infection and opportunistic infections areincreased [15,16]. Studies evaluated systemic lupus ery-
thematosus (SLE), JIA, polyangiitis with granulomatosis,
scleroderma, RA, and renal transplants, with influenza,
tetanus, PPSV-23, HiB, and hepatitis B virus (HBV) vac-
cines. In most, glucocorticoids impaired vaccine re-
sponse, and decreased cellular responses to diphtheria
and tetanus were reported in transplant patients receiv-
ing steroids.
Methotrexate
Many studies evaluated responses to vaccines with
MTX, most in RA, but also JIA, psoriatic arthritis, and
SLE [8,14,17-19]. Vaccines included PPSV-23, PCV-7,
HBV, influenza, MMR, the neoantigen keyhole limpet
hemocyanin (KLH), and delayed type hypersensitivity
(DTH) reactions. In 17 RA patients on MTX (mean dose
11.6 mg/week) responses to recombinant HBV protein
vaccine were seen in 68%, and use of MTX was not asso-
ciated with lack of response [14]. In two studies, RA pa-
tients on MTX responded similarly to healthy controls for
influenza [19], with GMTs significantly increased against
each strain; however, the percentage of responders was
lower in RA. Pneumococcal responses were also evaluated
with MTX, using PPSV-23 or PCV-7 [20]. In a direct com-
parison, responses to PPSV-23 were similar to those to
PCV-7; but MTX has emerged as a predictor of poor re-
sponse, with a greater effect than TNF inhibitors [20,21].
Figure 1 Immunomodulatory therapies. AZA, azathioprine; BAFF, B-cell activating factor; Blys, B lymphocyte stimulator; CHO, carbohydrate;
CTX, cyclophosphamide; CYCA, cyclosporine A; DTH, delayed type hypersensitivity; INF, interferon; inhib, inhibitor; LEF, leflunomide; MMF,
mycophenolate mofetil; M-TOR, mammalian target of rapamycin; MTX, methotrexate; SSZ, sulfasalazine; TLR, toll-like receptor; Tofa, tofacitinib;
Ustek, ustekinumab.
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20 RA patients on MTX monotherapy to tetanus toxoid
(TT), PPSV-23, KLH, and DTH. TT responses were seen
in only 42.3% on MTX, lower than that expected for
‘normal’ controls (>70 to 80%) [18]. Responses to PPSV-23
ranged from 29% to 61% for individual serotypes, but 79%
responded to ≥3 serotypes. Ninety-three percent treated
with MTX had detectable anti-KLH IgG neoantigen re-
sponses, and most (70%) maintained positive DTH re-
sponse. In a more recent study, 23 RA patients on MTX
monotherapy had similar reductions in TT (39% re-
sponders) and PPSV-23 responses (70.8% with 6 sero-
types) [22].
In 10 JIA patients on MTX who received MMR
booster vaccinations, those treated with MTX alone had
reduced humoral responses, and while there was no re-
duction in titer with MTX plus TNF inhibitors, markers
of cell-mediated immunity were reduced [8]. Seroprotec-
tion rates and GMT for mumps, rubella, diphtheria, andtetanus were recently reported to be lower in JIA than
controls, but unrelated to MTX exposure [23].
In summary, MTX may reduce response in patients
receiving some protein antigens (influenza and TT) but
retention of others (for example, KLH). Reductions in
polysaccharide and conjugated pneumococcal responses
are reported, but most individuals mount responses to
multiple serotypes. The safety of live virus booster vac-
cines was demonstrated for MMR with MTX, and zoster
vaccines may also be administered to these patients.
Other non-biological DMARDs
Immunization efficacy was studied with chloroquine and
hydroxychloroquine (HCQ) in SLE and RA, and healthy
individuals for malaria prophylaxis [24]. Responses to
yellow fever, oral polio, oral cholera and typhoid vaccines,
PPSV-23, human papilloma virus (HPV), and influenza
vaccines were analyzed. Little or no impairment in
responses were reported with anti-malarials [25].
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yellow fever vaccine occurred. One study evaluated
immunogenicity and safety of HPV vaccine in 50 women
with SLE and 50 healthy controls; among the 66% of SLE
patients on HCQ, there was no significant reduction in
seroconversion rates [26].
Immunization efficacy with sulfasalazine (SSZ) has also
been studied [27,28]. In one study, responses to TT or
inactivated influenza were evaluated in 23 healthy subjects
receiving SSZ or placebo, demonstrating a significant re-
duction in IgG and IgA anti-tetanus-producing cells [27].
In a contrasting study, SSZ had no effect on immunization
responses to adjuvented pandemic influenza vaccine [25].
In seven JIA patients on SSZ only one was a ‘low re-
sponder,’ to MCV-4 [29].
Vaccination responses with leflunomide have not been
well-studied. Ribeiro and colleagues [30] evaluated im-
mune responses to the trivalent influenza vaccine in RA.
Among 340 patients on combinations of DMARDs
(42.9% on leflunomide) compared with 230 healthy con-
trols, leflunomide use was not associated with decreased
immune response.
Azathioprine
A considerable amount of data is available for AZA in
patients with SLE, inflammatory arthritis, polyangiitis
with granulomatosis, and renal transplant using different
vaccines (influenza, injectable typhoid, PPSV, TT, and
HiB) [31-33]. Studies of influenza responses are conflic-
ting between reports, with some showing no reductions
in responses [32] and others demonstrating decreased
seroconversion, reduction in GMTs, and fewer four-fold
titer increases with AZA [31,32]. Responses to other
vaccines, including TT, PPSV-23, HBV, and the HPV
vaccine were not, however, significantly decreased with
AZA. Across these studies variable endpoints were used
to define a response [26].
Mycophenolate
Influenza vaccine responses, seroprotection rates, and
seroconversion rates were reduced with mycophenolate
(MMF) compared with AZA in transplant recipients
[34]. In another transplant study that evaluated cellular,
humoral, and recall responses to PPSV and TT vaccines,
patients on MMF were unable to mount a primary
humoral or recall response to TT and PPSV-23, and cel-
lular responses to TT were also reduced [35]. With the
HPV vaccine in SLE, those on MMF had reduced sero-
conversion rates for two genotypes compared with pa-
tients receiving other immunodulators (HCQ, AZA, and
calcineurin inhibitors), and titers were inversely corre-
lated with MMF dose [26]. There are limited data on the
more potent immunosuppressant, cyclophosphamide, in
rheumatic diseases. The response to PPSV-23 in twopatients with systemic sclerosis on cyclophosphamide
was severely impaired [36].
Cyclosporine and calcineurin inhibitors
The effects of cyclosporine (CycA) on immune re-
sponses have been studied in transplant recipients with
influenza, KLH, TT, and HBV [37,38]. In these studies,
controls were typically patients receiving other immu-
nomodulators (for example, AZA, MMF, sirolimus), and
usually steroids [35,39]. In one study, CycA-treated pa-
tients had a lower immune response against influenza A
than AZA-treated patients, and boosters were not ef-
fective. Another group reported significantly decreased
responses to influenza with CycA compared with siroli-
mus in lung transplants. In CycA-treated chronic uveitis
patients, significantly decreased DTH was seen, but
without differences in responses to KLH or TT [37].
Biologics
Tumor necrosis factor inhibitors
Several studies, mostly in RA, have evaluated immuni-
zations with TNF inhibitors [17,21,39-42]. Influenza and
pneumococcal responses were the focus of most, but
MMR was studied in JIA. Overall, vaccination with TNF
monotherapy was effective, but a combination of MTX
with TNF inhibitors showed significantly decreased re-
sponses [20,21]. In two JIA studies with the conjugate
pneumococcal vaccine (PCV-7) or MMR re-vaccination,
MTX and etanercept did not decrease responses. One
small study demonstrated that there was no reduction in
DTH responses with etanercept [43]. Although live virus
vaccines are not recommended in patients receiving bio-
logics, the incidence of herpes zoster in patients recei-
ving TNF inhibitors was not increased compared with
non-biological DMARDs [6]. Although a small study re-
ported that booster live attenuated yellow fever vaccines
did not cause illness, these were recall responses and not
first exposure to the vaccine [9]. Overall, the available
data would support that vaccination with non-live vi-
ruses in patients receiving TNF inhibitors may have
slight reductions in response, but these are likely pro-
tective. While some data suggest that certain live virus
vaccines eliciting booster or recall responses may be safe
in patients receiving TNF inhibitors (for example, zoster,
MMR), extrapolation to live organism neoantigen immu-
nizations cannot be assumed, and additional studies are
necessary.
Abatacept
Immunization responses with abatacept, which blocks
T-cell activation via co-stimulatory pathways, were
studied in RA, psoriasis, and healthy controls. In healthy
individuals, abatacept did not inhibit responses to TT or
PPSV-23 [44]. Patients with RA on abatacept vaccinated
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[45], with only 48% mounting a response to ≥3 sero-
types. Psoriasis patients on abatacept showed decreased
responses to both the bacteriophage PhiX and KLH
neoantigens [46]. A recent open-label study reported the
efficacy of PPSV-23 and seasonal influenza vaccines in
RA patients taking subcutaneous abatacept plus back-
ground DMARDS. In those without protective titers at
baseline, 73.9% mounted a response to PPSV-23 (defined
as a two-fold increase in three out of five antigens), with
83.9% developing protective titers. Only 61.3% had a re-
sponse to influenza vaccine (four-fold increase in two out
of three antigens), but 82.1% had protective titers [47].
Rituximab
By inhibiting B cells, rituximab (RTX) may affect hu-
moral immunity as evidenced by total IgM and IgG
slowly declining with repeated administration. In rheu-
matic disease patients, a number of studies have eva-
luated vaccine responses with RTX with influenza TT,
PPSV-23, DTH, and KLH, mostly in RA [19,48]. In a
large study of RA patients on RTX and MTX, immuni-
zations were given after a first course of RTX during the
period of B-cell depletion. Responses to TT and DTH were
preserved at 24 weeks compared with MTX alone, but
neoantigen responses (KLH) and responses to PPSV-23
were significantly reduced [18]. In other RA studies,
patients on RTX had significantly diminished responses
to influenza vaccine, with one group showing better
responses as a booster response than as a neoantigen
[19,48]. Although humoral responses were reduced, T-cell
responses to vaccine antigens were similar with RTX com-
pared with other DMARDs [49]. Because patients treated
with RTX may have potentially fatal reactivation of latent
viral infections, live virus vaccines should be strictly
avoided. Current vaccine studies of RTX are limited to
treatment with a single course of therapy. Whether re-
sponses would be impaired further with subsequent
courses requires additional study.
Belimumab
A recent study reported responses to PPSV-23, in-
fluenza, and TT vaccines in SLE patients receiving beli-
mumab directed against the cytokine B lymphocyte
stimulator involved in plasma cell differentiation [50].
Belimumab had no significant effect on the maintenance
of antibody titers in previously vaccinated patients, but
there were no controls, and vaccine exposure was not
standardized.
Tocilizumab
Interleukin (IL)-6 has pleiotropic activity, including ef-
fects on B-cell and T-cell differentiation and develop-
ment. In a small open-label study protective antibodytiters to influenza were reached in over 70% of toci-
lizumab (TCZ)-treated RA patients [51]. A controlled
study (TCZ plus MTX versus MTX) was conducted in
RA patients who received TCZ (8 mg/kg), with TT and
PPSV-23 given after 3 weeks and responses measured at
8 weeks after one additional TCZ infusion. Numerically
more patients responded to PPSV-23 based on a two-
fold increase in titer in ≥6 serotypes with MTX versus
TCZ plus MTX (70.8% versus 60%), but confidence in-
tervals were overlapping. Responses to TT were seen in
only 39% of patients receiving MTX alone, but not
further attenuated with TCZ plus MTX (42%) [52]. A
limitation of this study was exposure to only two TCZ
infusions at the time of immunization. To date, no in-
formation is available using other IL-6 inhibitors in
development.
Ustekinumab
There has been increasing appreciation of the role of the
IL-12/23 and IL-17 pathways in several rheumatic
diseases. Ustekinumab (UST), which binds and inhibits
signaling by both IL-12 and IL-23, has been approved
for the treatment of psoriatic arthritis. Responses to TT
and PPSV-23 were examined in patients with psoriasis
receiving prolonged treatment with UST (n = 60) and
compared with a control group of psoriasis patients not
taking systemic therapy (n = 56). There was no demon-
strable impairment in responses to PPSV-23; >2-fold in-
creases were seen for ≥7 of 14 pneumococcal serotypes
in 96.6% of UST-treated patients and 92.6% of controls.
Similarly, there was no decrement in responses to TT
(≥4-fold increase) in patients following vaccination, with
84.7% of UST-treated and 77.8% of controls having re-
sponses. Cellular responses to TT were also examined
and showed no difference between groups [53].
Interleukin-1 inhibitors
There is limited information on immunization responses
in patients receiving anakinra, an IL-1 receptor antagon-
ist approved for RA, the IL-1R-Accessory Protein fusion
protein rilonacept, or the anti-IL1-β antibody canaki-
numab. The effects of anakinra on vaccine antibody re-
sponses in patients with RA were studied, but these
results have never been presented.
Tofacitinib
The most recently approved agent in the US for the treat-
ment of RA is the Janus kinase (Jak) inhibitor tofacitinib,
which preferentially blocks Jaks 1 and 3, with additional
Jak inhibitors in development. While not ‘biologic’ in
terms of its molecular structure, it inhibits downstream
activities of multiple cytokine and growth factors, includ-
ing IL-6 and the T-cell cytokines IL-2 and interferons. To
date, only abstract data have been presented concerning
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PPSV-23 and influenza vaccines were administered to
patients taking long-term tofacitinib, some stopping tofa-
citinib 2 weeks before immunization and others without
tofacitinib interruption. There was no significant diffe-
rence in response to PPSV-23 (>2-fold increase in 6 of 12
antigens; 75% versus 84.6%) or influenza (>4-fold increase
in 2 of 3 antigens; 66.3% versus 61.8%) between conti-
nuous exposure and 2-week tofacitinib withdrawal, but
titers were higher in those taken off tofacitinib before
immunization [54]. A larger study was conducted in RA
patients on 10 mg bid of tofacitinib alone or placebo
stratified for MTX use using influenza and PPSV-23 vac-
cines, with response measured at 35 days. Similar propor-
tions of patients had responses to influenza (≥4-fold
increase in 2 of 3 antigens) in tofacitinib versus placebo
(56.9% versus 62.2%) with some reductions seen in those
on MTX. With PPSV-23, only 45.1% of those on tofaciti-
nib had a response (≥2-fold increase in 6 of 12 antigens)
compared with 68.4% on placebo, with the differences
most notable in those on MTX versus no MTX as co-
therapy [54,55]. As with other immunomodulators, live
virus vaccines in patients treated with tofacitinib should
be avoided.
Conclusion
Immunizations remain an important component of risk
mitigation for patients receiving immunomodulatory
therapies, but there are important caveats to consider
for individual patients and with specific drugs in terms
of efficacy and potentially with safety. Vaccines remain
immunogenic, although responses may be somewhat
attenuated with certain drugs. The magnitude of the im-
mune response to vaccines in RA depends on 1) pre-
existing memory at the T- and B-cell level as the antigen
and co-stimulatory threshold requirements are lower for
memory populations, 2) the nature of the immunosup-
pressant (B-cell depleting versus others), 3) the timing of
vaccination, and 4) whether or not the vaccine is adju-
vented. The optimal time for administration to achieve op-
timal titers and memory is ideally before the initiation of
immunomodulators, though this may not always be pos-
sible. Most routine vaccinations should be administered
according to current guidelines to all patients with rheu-
matic diseases taking immunosuppressive medications.
Live vaccines should be avoided in patients taking
most immunosuppressive and immunomodulatory the-
rapies, ideally administered prior to DMARD initiation.
The zoster vaccination may be safe in patients receiving
MTX, AZA, or moderately dosed prednisone. While
MMR has been administered as a booster to children
taking MTX and TNF inhibitors without reported se-
quelae, this has not been formally studied. There are
limited data regarding the safety of other live virusvaccines (for example, intranasal influenza, yellow fever)
in rheumatic disease patients taking DMARDs or bio-
logics. While possible, live viral shedding from house-
hold members or close contacts to rheumatic disease
patients taking immunosuppressive therapies has not
been well documented. If live virus vaccines are required
in patients on immunosuppressives, there is no evidence
base upon which to provide guidance for how long a pa-
tient should be off a particular agent before receipt of
the vaccine; this would need to factor in both the
pharmacokinetics as well as the pharmacodynamics of
individual compounds. The potential of utilizing a com-
bination of human monoclonal antibodies against infec-
tious agents may be a focus of future applications and
could expand vaccine applications.
Recommendations for vaccination in patients with
rheumatic diseases have been published by EULAR and
ACR based on available evidence and expert consensus.
Since their publication, a number of new drugs have
been approved, and additional data have been presented
as abstracts and manuscripts for already approved drugs
discussed in this paper, and additional vaccine recom-
mendations have been issued regarding immunizations
in general and in the immunocompromised. These
include recommendations for pertussis inclusion with
tetanus boosters in all individuals, given the resurgence
of whooping cough and waning immunity in adults and
recommendations for the conjugated PCV-13 in im-
munosuppressed adults followed by PPSV-23.
More controlled studies are needed to evaluate immu-
nization efficacy with existing agents and as part of the
evaluation of new drugs. To interpret such data, controls
with the disease under study taking an alternative stan-
dard regimen (for example, MTX in RA studies) and
healthy controls are needed. The current lack of standard-
ized reporting of results from immunization studies makes
cross-study comparisons difficult. Additional evaluation of
humoral and cellular immune responses following pro-
longed periods of immunomodulatory use is needed. Fi-
nally, studying booster immunizations for suboptimal
responders and to maintain titers in those on immuno-
suppressants, and the optimal timing of vaccine adminis-
tration are also areas that merit further investigation.
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